文献速递肝病

两步临床护理路径在代谢功能障碍相关脂肪性肝病中的预后性能

Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver disease.
PubMed 文献 · J Hepatol · 2025-01-23

VCTE-Prognosis研究在16中心纳入12,950例MASLD患者,评估FIB-4联合VCTE-LSM两步法对肝脏相关事件的预后性能。中位随访47个月,248例(1.9%)发生LRE,低、中、高危组5年累积发生率分别为0.5%、1.0%和10.8%。以LSM<10 kPa和>15 kPa划分中间FIB-4患者可缩小中间风险区并保持预测性能。

要点

  • FIB-4联合VCTE-LSM两步法可有效区分MASLD患者的不同LRE风险。
  • 低、中、高危组5年LRE累积发生率分别为0.5%、1.0%和10.8%。
  • 以LSM<10 kPa和>15 kPa划分中间FIB-4患者可缩小中间风险区并保持预测性能。

核心结论

  • FIB-4联合LSM的无创两步法可有效对MASLD患者进行LRE风险分层。
  • 研究结果支持各区域指南基于无创检测诊断进展性肝纤维化的临床护理路径推荐。

研究设计与样本

  • VCTE-Prognosis研究为纵向研究,纳入在美国、欧洲和亚洲16个中心接受VCTE检查并随访临床事件的MASLD患者。
  • 共纳入12,950例患者,平均年龄52岁,女性占41%,12.1%的患者LSM>12 kPa。
  • 主要终点为肝脏相关事件(LRE),定义为肝功能失代偿和/或肝细胞癌。

主要发现

  • 基线FIB-4以1.3(年龄≥65岁用2.0)和2.67为界,将66.3%归为低危、9.8%归为高危,23.9%处于中间风险区。
  • 中间FIB-4患者若LSM<8.0 kPa归为低危、>12.0 kPa归为高危后,全队列低、中、高危分别占81.5%、4.6%、13.9%。
  • 中位随访47个月(IQR 23-72)期间,248例(1.9%)发生LRE。
  • 低、中、高危组5年LRE累积发生率分别为0.5%、1.0%和10.8%。
  • 以Agile 3+、Agile 4和FAST替代LSM未缩小中间风险区或改善事件预测。

关键数值与推荐

  • 中间FIB-4患者以LSM<10 kPa归为低危、>15 kPa归为高危,可缩小中间风险区并保持预测性能。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Current guidelines recommend a two-step approach for risk stratification in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) involving Fibrosis-4 index (FIB-4) followed by liver stiffness measurement (LSM) by vibration-controlled transient elastography (VCTE) or similar second-line tests. This study aimed to examine the prognostic performance of this approach. METHODS: The VCTE-Prognosis study was a longitudinal study of patients with MASLD who had undergone VCTE examinations at 16 centres from the US, Europe and Asia with subsequent follow-up for clinical events. The primary endpoint was incident liver-related events (LREs), defined as hepatic decompensation and/or hepatocellular carcinoma. RESULTS: Of 12,950 patients (mean age 52 years, 41% female, 12.1% LSM >12 kPa), baseline FIB-4, at cut-offs of 1.3 (or 2.0 for age ≥65) and 2.67, classified 66.3% as low-risk and 9.8% as high-risk, leaving 23.9% in the intermediate-risk zone. After classifying intermediate FIB-4 patients as low-risk if LSM was <8.0 kPa and high-risk if LSM was >12.0 kPa, 81.5%, 4.6%, and 13.9% of the full cohort were classified as low-, intermediate-, and high-risk, respectively. At a median (IQR) follow-up of 47 (23-72) months, 248 (1.9%) patients developed LREs. The 5-year cumulative incidence of LREs was 0.5%, 1.0% and 10.8% in the low-, intermediate- and high-risk groups, respectively. Replacing LSM with Agile 3+, Agile 4, and FAST did not reduce the intermediate-risk zone or improve event prediction. Classifying intermediate FIB-4 patients by LSM <10 kPa (low-risk) and >15 kPa (high-risk) reduced the intermediate-risk zone while maintaining predictive performance. CONCLUSIONS: The non-invasive two-step approach of FIB-4 followed by LSM is effective in classifying patients at different risks of LREs. IMPACT AND IMPLICATIONS: Metabolic dysfunction-associated steatotic liver disease (MASLD) is emerging as one of the leading causes of cirrhosis and hepatocellular carcinoma worldwide, but only a minority of patients will develop these complications. Therefore, it is necessary to use non-invasive tests instead of liver biopsy for risk stratification. Additionally, as most patients with MASLD are seen in primary care instead of specialist settings, cost and availability of the tests should be taken into consideration. In this multicentre study, the use of the Fibrosis-4 index followed by liver stiffness measurement by vibration-controlled transient elastography effectively identified patients who would later develop liver-related events. The results support current recommendations by various regional guidelines on a clinical care pathway based on non-invasive tests to diagnose advanced liver fibrosis.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Yip TC, Lee HW, Lin H, et al. Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver disease. J Hepatol. 2025. PMID: 39863175. doi:10.1016/j.jhep.2025.01.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。